Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Chemotherapy versus Chemotherapy Alone in Non-Small Cell Lung Cancer: A Propensity Score and Inverse Probability Treatment Weighting Analysis

被引:2
|
作者
Zhao, Junfeng [1 ]
Hao, Shaoyu [2 ]
Li, Ying [3 ]
Liu, Xiaoman [4 ]
Liu, Zhaoxuan [5 ]
Zheng, Chunhui [6 ]
Han, Dan [1 ]
机构
[1] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Shandong, Peoples R China
[2] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Thorac Surg, Jinan, Shandong, Peoples R China
[3] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Med Oncol, Jinan, Shandong, Peoples R China
[4] BinZhou Med Univ, Affiliated Hosp, Dept Oncol, Binzhou, Shandong, Peoples R China
[5] BinZhou Med Univ, Zibo Ctr Hosp, Dept Oncol, Zibo, Shandong, Peoples R China
[6] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Breast Canc Ctr, Jinan, Peoples R China
关键词
neoadjuvant immunotherapy; neoadjuvant chemotherapy; non-small cell lung cancer; propensity score matching; inverse probability of treatment weighting; lung cancer resection; immune checkpoint inhibitor; SINGLE-ARM; OPEN-LABEL; SURGERY; TRIAL; PEMBROLIZUMAB; MULTICENTER; RESECTION;
D O I
10.2147/ITT.S437911
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose: This study aimed to compare the efficacy and safety of neoadjuvant chemotherapy (NCT) and neoadjuvant immunotherapy combined with chemotherapy (NICT) combined with radical lung cancer resection for the treatment of patients with resectable non small cell lung cancer (NSCLC). To adjust for confounding factors, we innovatively adopted two matching methods: propensity score (PS) and inverse probability of treatment weighting (IPTW).Patients and Methods: We conducted a retrospective analysis of the clinicopathological features and prognosis of patients with resectable NSCLC treated with NCT or NICT combined with radical lung cancer resection using propensity score matching (PSM) at a ratio of 1:1 and IPTW to balance potential bias.Results: After PSM, 116 pairs of patients who had undergone NCT or NICT were selected for the final analysis. The pathological complete remission (pCR) and major pathological remission (MPR) rates were significantly better in the NICT group than in the NCT group (pCR rate of 44.8% vs 2.6%, P< 0.001; MPR rate of 66.4% vs 20.7%, P< 0.001). No significant difference was seen between the NICT and NCT groups in terms of postoperative complications (12.1% vs 9.5%, P=0.182). Patients in the NICT group had significantly better disease-free survival (DFS) and overall survival(OS) than those in the NCT group ([3-year DFS: 75.2% vs 43.3%, P< 0.001] and [3-year OS: 91.5% vs 58.0%, P< 0.001]). Among all patients, those with postoperative pathology of pCR had better DFS (P< 0.001) and OS (P= 0.009). Patients with postoperative pathology of MPR had better DFS (P< 0.001) and OS (P< 0.001). The IPTW method yielded similar pathologic and prognostic results.Conclusion: Patients with resectable NSCLC treated with NICT had better pathological responses and prognosis, than those treated with NCT, and the safety profiles of NICT and NCT were similar.
引用
收藏
页码:113 / 133
页数:21
相关论文
共 50 条
  • [1] Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer
    Wang, Xue
    Niu, Xiaomin
    An, Na
    Sun, Yile
    Chen, Zhiwei
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [2] Non-small cell Lung Cancer: Neoadjuvant Chemotherapy versus adjuvant Chemotherapy
    Lorenz, Judith
    [J]. ZENTRALBLATT FUR CHIRURGIE, 2019, 144 (03): : 215 - +
  • [3] Safety and Efficacy of Neoadjuvant Chemoimmunotherapy versus Chemotherapy for Non-Small Cell Lung Cancer Undergoing Sleeve Resection
    Qiu, Yanjun
    Yu, Jinjiang
    Guo, Quanmin
    Xu, Jingyan
    [J]. CANCER MANAGEMENT AND RESEARCH, 2024, 16 : 1221 - 1230
  • [4] Meta-analysis of the literature: Neoadjuvant chemotherapy versus surgery alone in non-small cell lung cancer
    Dan, L.
    Zhu, B.
    Chen, Z.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non-small cell lung cancer in real world
    Fang, Min
    Hang, Qingqing
    Jiang, Haitao
    Cai, Lei
    Hu, Jinlin
    Ying, Hangjie
    Gu, Qing
    Yu, Xiaofu
    Liu, Jinshi
    Lai, Xiaojing
    [J]. FRONTIERS IN ONCOLOGY, 2023, 12
  • [6] Neoadjuvant chemotherapy in non-small cell lung cancer
    Niklinski, J
    [J]. 8TH CENTRAL EUROPEAN LUNG CANCER CONFERENCE, 2002, : 217 - 223
  • [7] Neoadjuvant chemotherapy for non-small cell lung cancer
    Pinder-Schenck, M.
    Bepler, G.
    [J]. MINERVA CHIRURGICA, 2009, 64 (06) : 611 - 628
  • [8] Neoadjuvant chemotherapy in non-small cell lung cancer
    Felip, E
    Rosell, R
    [J]. CURRENT MEDICINAL CHEMISTRY, 2002, 9 (08) : 893 - 898
  • [9] The Efficacy and Safety of Neoadjuvant Immunotherapy in Patients with Non-Small Cell Lung Cancer
    Guven, Deniz Can
    Sahin, Taha Koray
    Kilickap, Saadettin
    [J]. CANCERS, 2024, 16 (01)
  • [10] Effectiveness and Safety of Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer: A Meta-Analysis
    Li, Baofeng
    Zhang, Guangxin
    Jin, Chengyan
    Zhao, Yinghao
    Hua, Peiyan
    Tong, Ti
    [J]. INDIAN JOURNAL OF SURGERY, 2023, 85 (SUPPL 2) : 584 - 596